{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:26:05Z","timestamp":1792661165424,"version":"4.5.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:00:00Z","timestamp":1426032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0118564","type":"journal-article","created":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T17:49:25Z","timestamp":1426096165000},"page":"e0118564","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":226,"title":["Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Na\u00efve Patients with Metastatic Uveal Melanoma"],"prefix":"10.1371","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01355120","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lisa","family":"Zimmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Vaubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Utikal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Enk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhart","family":"K\u00e4mpgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Bluhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Rompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus G.","family":"Griewank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,3,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: trends in incidence, treatment, and survival","volume":"118","author":"AD Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26","volume":"123","author":"M Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"CD Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"CD Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00008390-200412000-00003","article-title":"BRAF mutations are detectable in conjunctival but not uveal melanomas","volume":"14","author":"HE Spendlove","year":"2004","journal-title":"Melanoma Res"},{"key":"ref6","first-page":"5761","article-title":"Absence of BRAF and NRAS mutations in uveal melanoma","volume":"63","author":"F Cruz 3rd","year":"2003","journal-title":"Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.2013.312","article-title":"TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours","volume":"109","author":"KG Griewank","year":"2013","journal-title":"Br J Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","article-title":"Effectiveness of treatments for metastatic uveal melanoma","volume":"148","author":"JJ Augsburger","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/cam4.133","article-title":"Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives","volume":"2","author":"K Buder","year":"2013","journal-title":"Cancer Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","volume":"311","author":"RD Carvajal","year":"2014","journal-title":"JAMA"},{"issue":"5s (Suppl)","key":"ref11","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1200\/jco.2014.32.15_suppl.9030","article-title":"Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma [abstract]","volume":"32","author":"S Piperno-Neumann","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"GS Falchook","year":"2012","journal-title":"The Lancet Oncology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e48787","DOI":"10.1371\/journal.pone.0048787","article-title":"Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512","volume":"7","author":"S Bhatia","year":"2012","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2249.2009.03912.x","article-title":"Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists","volume":"157","author":"KS Peggs","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"FS Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"C Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"5s (Suppl)","key":"ref17","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1200\/jco.2014.32.15_suppl.9033","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial [abstract]","volume":"32","author":"J Piulats Rodriguez","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1093\/annonc\/mdt376","article-title":"Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma","volume":"24","author":"M Maio","year":"2013","journal-title":"Ann Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","article-title":"Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy","volume":"61","author":"R Danielli","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3109\/0284186X.2013.786839","article-title":"Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)","volume":"52","author":"S Kelderman","year":"2013","journal-title":"Acta Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/CMR.0b013e32835b554f","article-title":"Ipilimumab activity in advanced uveal melanoma","volume":"23","author":"MA Khattak","year":"2013","journal-title":"Melanoma Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/cncr.28282","article-title":"Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience","volume":"119","author":"JJ Luke","year":"2013","journal-title":"Cancer"},{"issue":"5s (Suppl)","key":"ref23","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/jco.2014.32.15_suppl.3060","article-title":"Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients [abstract]","volume":"32","author":"MA Deo","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"CM Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"EA Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"JD Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/CMR.0b013e3283610586","article-title":"Treatment of metastatic uveal melanoma with intravenous fotemustine","volume":"23","author":"F Spagnolo","year":"2013","journal-title":"Melanoma Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CMR.0b013e3283403ce9","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma","volume":"20","author":"J Homsi","year":"2010","journal-title":"Melanoma Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"S Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"issue":"5s (Suppl)","key":"ref30","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/jco.2014.32.15_suppl.9007","article-title":"Comparative health care (HC) costs in patients (pts) with metastatic melanoma (mM) [abstract]","volume":"32","author":"C-L Chang","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival","volume":"116","author":"GY Ku","year":"2010","journal-title":"Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","article-title":"Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival","volume":"24","author":"J Delyon","year":"2013","journal-title":"Ann Oncol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"SL Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"SL Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"O Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"JR Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"Supp","key":"ref37","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1200\/jco.2013.31.15_suppl.9010","article-title":"Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM) [abstract]","volume":"31","author":"O Hamid","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref38","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","author":"C Robert","year":"2014","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1167\/iovs.07-1606","article-title":"PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro","volume":"49","author":"W Yang","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications","volume":"37","author":"AM Di Giacomo","year":"2010","journal-title":"Semin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0118564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T18:35:24Z","timestamp":1598812524000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0118564"}},"subtitle":[],"editor":[{"given":"Jose Luis","family":"Perez-Gracia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,11]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0118564","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,11]]}}}